Citation

Carandang C, Robbins D, Mullany E, Yazbek M, Minot S. J. Can. Acad. Child Adolesc. Psychiatry 2007; 16(1): 1-8.

Affiliation

Dalhousie University, Department of Psychiatry, Halifax, Nova Scotia, Canada. carlo.carandang@iwk.nshealth.ca

Copyright

(Copyright © 2007, Canadian Academy of Child and Adolescent Psychiatry)

DOI

unavailable

PMID

18392173

PMCID

PMC2276172

Abstract

INTRODUCTION: Treatment nonresponse in adolescent mood disorders is a major public health problem, as mood disorders in youth are associated with significant mortality by suicide, protracted course of illness, and recurrence into adulthood. Three studies with small sample sizes exist for lamotrigine in youth mood disorders. However, the risk of serious rash has limited its use in youth mood disorders. OBJECTIVE: The aims of this study are to evaluate the preliminary effectiveness and safety of lamotrigine in adolescent mood disorders. METHODS: Medical charts were retrospectively reviewed at three clinical sites for 42 adolescents treated with lamotrigine for a mood disorder. The Clinical Global Impression (CGI) Severity and Improvement scores were obtained at baseline and last visit. Treatment-emergent adverse effects were also obtained. RESULTS: Improvement was seen in 22 subjects (52%). The mean daily lamotrigine dose was 114.8mg (SD 75.6), and the average duration of lamotrigine treatment was 29.1+/-31.8 weeks. The mean CGI-S score decreased from 4.9+/-1.0 at baseline to 3.5+/-1.4 at endpoint (z=3.204, p<0.002). Four subjects (10%) developed benign rash. CONCLUSIONS: This study provides preliminary data that lamotrigine may be effective in adolescents with mood disorders. However, this study revealed that lamotrigine might be associated with a significant risk of benign rash.

Language: en